Thanks for the updates Steve. Regarding cash, there's also the $25M from Sanofi for completing the Alport phase 2 trial which I believe is due at the end of phase 2. The trial record was last updated in Sep 21 and is about a year placebo controlled followed by a year open label and is now due to complete in Dec 23. Target enrolment is 45 patients and they have 23 centres recruiting around the world which should mitigate any frther covid delays. To meet the Dec 23 completion date they must be about to complete enrolment.
In terms of the milestone payment, I wonder what counts as the end of phase 2? Is it the end of blinded part of the study or the end of the open label part? Hopefully its the former and the cash will arrive before they have to access alternative sources of finance.